Clinically, elevated levels of serum/plasma HSP90α are associated with malignant progression in CRC, non-small cell lung cancer, breast carcinoma, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and glioblastoma [44–47]. Here, HSP90AA1 is linked to glioblastoma.